Key Metrics
CiteScore 

5.4
Impact Factor 

5 - 10
Scite Index 

0.90 5-Year SI

SJR 

Q3Hematology

SNIP 

0.9
Recommended pre-submission checks
Powered by 

Topics Covered on HemaSphere
HemaSphere Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 1200 |
| Publication Time | 7 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | European Hematology Association |
| Frequency | Monthly |
| Publication Start Year | 2017 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Other charges | Visit website |
| Publication Time | 7 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC, CC BY-SA, CC BY-NC-ND, CC BY-ND, CC BY-NC-SA |
| OA statement | Visit website |
View less
Planning to publish in HemaSphere ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in HemaSphere
Correction to \u201cEHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation\u201d
- 7 Aug 2026
- HemaSphere
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high\u2010risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
- 6 Aug 2026
- HemaSphere
The case for targeting enhancer regions in high\u2010risk TCF3::HLF\u2010positive B\u2010cell acute lymphoblastic leukemia
- 6 Aug 2026
- HemaSphere
Therapeutic success and epidemiological failure in hematology
- 4 Aug 2026
- HemaSphere
First\u2010line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
- 4 Aug 2026
- HemaSphere
Passenger variants as pan-clonal markers of pediatric AML: Implications for molecular MRD.
- 1 Aug 2026
- HemaSphere
Correction to \u201cEHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation\u201d
- 7 Aug 2026
- HemaSphere
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high\u2010risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
- 6 Aug 2026
- HemaSphere
The case for targeting enhancer regions in high\u2010risk TCF3::HLF\u2010positive B\u2010cell acute lymphoblastic leukemia
- 6 Aug 2026
- HemaSphere
Therapeutic success and epidemiological failure in hematology
- 4 Aug 2026
- HemaSphere
First\u2010line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
- 4 Aug 2026
- HemaSphere
Passenger variants as pan-clonal markers of pediatric AML: Implications for molecular MRD.
- 1 Aug 2026
- HemaSphere
FAQs on HemaSphere
How long has HemaSphere been actively publishing? 
What is the publishing frequency of HemaSphere? 
How many articles did HemaSphere publish last year? 
What is the eISSN & pISSN for HemaSphere? 
What is Citescore for HemaSphere? 
What is SNIP score for HemaSphere? 
What is the SJR for HemaSphere? 
Who is the publisher of HemaSphere? 
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary